Elena Olmastroni

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1008537/publications.pdf

Version: 2024-02-01

840585 642610 24 640 11 23 citations h-index g-index papers 24 24 24 601 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Achilles tendon ultrasonography in familial hypercholesterolemia: A subâ€study of the Lipid transPort disorders Italian GEnetic Network (LIPIGEN). Journal of Internal Medicine, 2022, 291, 702-704.	2.7	2
2	Potentially Inappropriate Prescribing among Elderly Outpatients: Evaluation of Temporal Trends 2012–2018 in Piedmont, Italy. International Journal of Environmental Research and Public Health, 2022, 19, 3612.	1.2	2
3	Twelve Variants Polygenic Score for Lowâ€Density Lipoprotein Cholesterol Distribution in a Large Cohort of Patients With Clinically Diagnosed Familial Hypercholesterolemia With or Without Causative Mutations. Journal of the American Heart Association, 2022, 11, e023668.	1.6	12
4	Statin use and risk of dementia or Alzheimer's disease: a systematic review and meta-analysis of observational studies. European Journal of Preventive Cardiology, 2022, 29, 804-814.	0.8	46
5	Evaluation of Factors Associated With Appropriate Drug Prescription and Effectiveness of Informative and Educational Interventions—The EDU.RE.DRUG Project. Frontiers in Pharmacology, 2022, 13, 832169.	1.6	2
6	Adherence to the Mediterranean Diet: Impact of Geographical Location of the Observations. Nutrients, 2022, 14, 2040.	1.7	19
7	The Effectiveness of Interventions to Evaluate and Reduce Healthcare Costs of Potentially Inappropriate Prescriptions among the Older Adults: A Systematic Review. International Journal of Environmental Research and Public Health, 2022, 19, 6724.	1.2	6
8	Reported muscle symptoms during statin treatment amongst Italian dyslipidaemic patients in the realâ€life setting: the PROSISA Study. Journal of Internal Medicine, 2021, 290, 116-128.	2.7	21
9	Gut Microbiota Functional Dysbiosis Relates to Individual Diet in Subclinical Carotid Atherosclerosis. Nutrients, 2021, 13, 304.	1.7	16
10	Interactions of Oxysterols with Atherosclerosis Biomarkers in Subjects with Moderate Hypercholesterolemia and Effects of a Nutraceutical Combination (Bifidobacterium longum BB536, Red) Tj ETQc	0 0.0 rgB1	√@verlock 10
11	Global epidemiology of dyslipidaemias. Nature Reviews Cardiology, 2021, 18, 689-700.	6.1	290
12	Sex-differences in factors and outcomes associated with adherence to statin therapy in primary care: Need for customisation strategies. Pharmacological Research, 2020, 155, 104514.	3.1	20
13	Geographical Variation in Medication Prescriptions: A Multiregional Drug-Utilization Study. Frontiers in Pharmacology, 2020, 11, 418.	1.6	7
14	A pragmatic controlled trial to improve the appropriate prescription of drugs in adult outpatients: design and rationale of the EDU.RE.DRUG study. Primary Health Care Research and Development, 2020, 21, .	0.5	4
15	Omega-3 polyunsaturated fatty acids supplementation and cardiovascular outcomes: do formulation, dosage, and baseline cardiovascular risk matter? An updated meta-analysis of randomized controlled trials. Pharmacological Research, 2020, 160, 105060.	3.1	30
16	Association between the cumulative exposure to bisphosphonates and hospitalization for atherosclerotic cardiovascular events: A population-based study. Atherosclerosis, 2020, 301, 1-7.	0.4	11
17	How registers could enhance knowledge and characterization of genetic dyslipidaemias: The experience of the LIPIGEN in Italy and of other networks for familial hypercholesterolemia. Atherosclerosis Supplements, 2020, 42, e35-e40.	1.2	10
18	Prevalence and relationship between metabolic syndrome and risk of cardiovascular disease: Evidence from two population-based studies. Atherosclerosis Supplements, 2020, 42, e41-e48.	1.2	8

#	Article	IF	CITATION
19	Multilevel Models to Estimate Carotid Intima-Media Thickness Curves for Individual Cardiovascular Risk Evaluation. Stroke, 2019, 50, 1758-1765.	1.0	23
20	Cardiovascular events with PCSK9 inhibitors: an updated meta-analysis of randomised controlled trials. Pharmacological Research, 2019, 143, 143-150.	3.1	25
21	Proprotein Convertase Subtilisin-Kexin type-9 (PCSK9) and triglyceride-rich lipoprotein metabolism: Facts and gaps. Pharmacological Research, 2018, 130, 1-11.	3.1	22
22	Evaluation of the performance of Dutch Lipid Clinic Network score in an Italian FH population: The LIPIGEN study. Atherosclerosis, 2018, 277, 413-418.	0.4	48
23	Epidemiology of cardiovascular risk factors in two population-based studies. Atherosclerosis Supplements, 2018, 35, e14-e20.	1.2	6
24	The Role of Registers in Increasing Knowledge and Improving Management of Children and Adolescents Affected by Familial Hypercholesterolemia: the LIPIGEN Pediatric Group. Frontiers in Genetics, 0, 13, .	1.1	4